Conatus Pharmaceuticals (CNAT) – Hot FDA News
-
Conatus Pharmaceuticals (CNAT) ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Didn't Meet Primary Endpoint
-
Conatus (CNAT) falls 45% after announcing emricasan did not have the desired effect in earlier-stage NASH fibrosis patients
-
-
-
-
Back to CNAT Stock Lookup